Capricor drops as deramiocel OLE data fails to quell regulatory concerns
Finance Desk
Capricor Therapeutics (CAPR) is down ~10% in Monday trading despite releasing positive data from an open-label extension study for deramiocel for Duchenne muscular dystrophy as investors appear hesitant that the candidate will muster US FDA approval.
